Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They ...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
Esperion stock holds Buy rating, $16 target from H.C. Wainwright
H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...
Esperion stock target cut to $4 by JMP Securities
JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...
Esperion price target lowered to $4 from $7 at JMP Securities
JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...
Esperion (ESPR) Receives a Sell from Bank of America Securities
In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion (ESPR – Research Report), with ...
Morningstar29d
Esperion Therapeutics Inc ESPR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...